Medical Management of Benign Prostatic Hyperplasia

Authors

  • Brijesh Kumar Singh NIMS Medical College, Jaipur, Rajasthan, India
  • Ravi Kumar Mathur NIMS Medical College, Jaipur, Rajasthan, India
  • Vansh Gopal Yadav NIMS Medical College, Jaipur, Rajasthan, India
  • Iqbal Singh NIMS Medical College, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.37591/rrjos.v3i1.1406

Abstract

Benign prostatic hyperplasia is one of the most prevalent diseases in elderly men. Medical therapies are targeted to relieve obstruction by relaxing smooth muscles(α-blocker) or promoting regression of the disease process (androgen ablation).Three major classes of drugs have been used for the medical management of BPH are α-adrenergic receptor antagonist, hormones and phytotherapy. Selective α 1 receptor antagonist is effective in the treatment of BPH. The development of specific α receptor antagonist such as tamsulosin with long half-life and no effect on blood pressure may offer improved tolerability over other selective α receptor antagonists.

 

Keywords: Hyperplasia, prostatic, adreno receptors

Downloads

Published

2019-04-15

Issue

Vol. 3 No. 1 (2014)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have neither given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.